Tobacco and cannabis use in the young 'Not in Employment, Education or Training' population: A systematic review and meta-analysis.

AddictionJun 1, 2026 (epub)
Clinical ResearchPreventive Medicine / Public Health

Clara Eyraud, Claire Collin, Philippe Martin et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined tobacco and cannabis use among NEET (Not in Employment, Education or Training) youth aged 15-29 years, comparing their usage patterns to those of employed youth and students. The study found a significant association between NEET status and increased tobacco use (OR = 1.92) and cannabis use (OR = 2.14), highlighting the need for targeted prevention strategies.

Key findings

  • NEET youth had a higher odds of tobacco use (OR = 1.92) compared to their peers.
  • Current cannabis use was significantly higher among NEET youth (OR = 2.14).
  • NEET youth showed a prevalence of cannabis use disorder at 31.93%, compared to 12.12% in non-NEET peers.
  • Current smoking was more prevalent in NEET youth compared to students (OR = 3.05).

Why it matters

Understanding the patterns of substance use among NEET youth is crucial for public health, as this population faces significant health challenges. Targeted interventions can help mitigate the long-term consequences associated with early substance use.

Source

PubMed · PMID 42225563

Published in Addiction. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Preventive Medicine / Public Health

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.